根据一份提交给美国证券交易委员会的文件披露,生物技术公司Allogene Therapeutics Inc. 已正式终止其与Overland Therapeutics达成的独家许可协议。此项终止决定将于2026年5月12日正式生效。
根据一份提交给美国证券交易委员会的文件披露,生物技术公司Allogene Therapeutics Inc. 已正式终止其与Overland Therapeutics达成的独家许可协议。此项终止决定将于2026年5月12日正式生效。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.